Tumour lysate particle loaded dendritic cell vaccine - Elios Therapeutics

Drug Profile

Tumour lysate particle loaded dendritic cell vaccine - Elios Therapeutics

Alternative Names: TL + YCWP + DC; TL-YCWP-DC; TLPLDC

Latest Information Update: 19 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Elios Therapeutics
  • Developer Cancer Insight; Elios Therapeutics; Perseus
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Malignant melanoma
  • Phase I/II Ovarian cancer
  • No development reported Solid tumours

Most Recent Events

  • 17 Apr 2018 Initial efficacy data from a phase IIb trial in Malignant Melanoma presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR - 2018)
  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Solid-tumours(Late-stage disease) in Cayman Islands (Parenteral)
  • 01 Apr 2017 Phase-I/II clinical trials in Ovarian cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) (Intradermal) before April 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top